Antiallergic agents (A61P37/08)

A   Human necessities(308602)
A61P37/08                     Antiallergic agents (antiasthmatic agents a61p0011060000; ophthalmic antiallergics a61p0027140000)(340)
Tricyclic nitrogen-containing derivatives of imidazo[4,5-c]pyridine, having inhibiting activity in response to hystamine 4 receptor (hh4r) // 2628074
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of formula 1 , or to a racemate, isomer, or pharmaceutically acceptable salt thereof, wherein X1 and X2 are C; each of X3 and X4 is independently C or N, provided that one of X3 and X4 is N; R1 is a saturated 4-9 member mono- or bi-heterocyclyl containing 1-2 heteroatoms (where the heteroatoms are N), where R1 is unsubstituted or substituted by 1 to 3 substituents selected from -NR6R7 and R8; or R1 is selected from -NR6R7 and R8; R2, R3, R4 and R5 may be the same or different; and each is independently selected from -H; -C1-C6alkyl; -C1-C6haloalkyl; -C1 -C6perhaloalkyl; -halogen (-F, -Cl, -Br, -I); -CN; -C1-C6talkoxy; -C1-C6haloalkoxy; -C1-C6perhaloalkoxy; C2alkenyl; -C2-C3alkynyl; -amino; -OH; -nitro (-NO2); -C6-C1aryl; and furan; provided that, when X3 is N, R4 is absent; and when X4 is N, R5 is absent, each of Y1, Y2, Y3, Y4 and Y5 is independently C or a heteroatom (preferably a heteroatom independently selected from N, O and S), provided that at least two of Y1, Y2, Y3, Y4 and Y5 are heteroatoms independently selected from N and O; each of Y2 and Y3 can be independently substituted by R9; Y4 may be substituted with -H or -C1-C6alkyl; each of R6 and R7 is independently selected from -H; -C1-C6alkyl; and -carboxyl (-COOH); R8 is -C1-C6alkyl or -C3cycloalkyl; and R9 is selected from -H; -C1-C6alkyl; and -C3cycloalkyl; wherein the alkyl and heterocyclyl may be independently unsubstituted or substituted by one or more substituents (for example, 1 to 3 substituents) selected from the group consisting of -C1-C4alkyl, -C1-C4alkoxy and -OH. The invention also relates to particular compounds and a pharmaceutical composition based on the said compounds.EFFECT: new heterocyclic compounds useful for human histamine receptor 4 inhibition are obtained.13 cl, 13 tbl, 144 ex
Aza-aryl-1-h-pyrazol-1-yl-sulphonamides // 2627268
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) ,in which radicals and characters have values specified in the claims and their versions. The proposed compounds act as potent antagonists of CCR (9) receptor. Animal testing has shown that these compounds are useful for treatment of inflammation, disease with a hallmark for CCR (9). The compounds as a whole are arylsulfamide derivatives and are used in pharmaceutical compositions, methods for treatment of CCR (9) mediated diseases and as a control in assays for identification of CCR (9) antagonists.EFFECT: increased efficiency of compounds application.26 cl, 2 tbl, 33 ex

1-phenyl-2-pyridinylalkyl alcohols derivatives as phosphodiesterase inhibitors // 2626956
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of general formula , where: R1 is selected from the group consisting of: methyl; trifluoromethyl; R2 is selected from the group consisting of: methyl optionally substituted with cyclopropyl; cyclopentyl; or R1 and R2, together with their interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) condensed with a phenyl group that carries -OR1 and -OR2 groups, where the asterisks indicate carbon atoms shared by such phenyl ring: , R19 is hydrogen; R3 is one or more substituents independently selected from halogen atoms; Z represents a -(CH2)n- group, where n is 0 or 1; A is a saturated and monocyclic (C3-C7) heterocycloalkylene group selected from the following list of di-radicals: , , , , , , , , , , where symbols [3] and [4] indicate the points of group A attachment to groups Z and K, respectively; K is selected from the group consisting of: -(CH2)mC(O)R4, where m can be 0 or 1; -C(O)(CH2)jR4, where j can be 1 or 2; -SO2(CH2)pR4, where p can be 0, 1 or 2; -(CH2)ySO2R4, where y can be 1 or 2; -(CH2)zR4, where z can be 1; and -C(O)(CH2)2SO2R4; R4 is a ring system which is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, selected from phenyl, (C3-C8) cycloalkyl, (C3-C7) heterocycloalkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH and O or heteroaryl, such ring is optionally substituted with one or more R5, which may be the same or different and which are independently selected from the group consisting of: (C1-C6) alkyl, optionally substituted with one or more groups independently selected from the list consisting of: -OH; (C3-C7) heterocycloalkyl(C1-C4)alkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH, O; 5-6 member heteroaryl where at least one ring carbon atom is replaced by a heteroatom selected from N and O; -OR6 group, where R6 is selected from the group consisting of (C1-C6) haloalkyl; -SO2R7 group, where R7 is (C1-C4) alkyl; and methyl optionally substituted with one or more (C3-C7) cycloalkyls; halogen atoms; CN; NR8R9, where R8 and R9 are different or identical and independently selected from the group consisting of: H; (C1-C4) alkylen-NR13 R14, where R13 and R14 are different or identical and independently selected from the group consisting of: a (C1-C6) alkyl, or they form a saturated (C3-C7) heterocyclic ring together with the nitrogen atom to which they are attached; -SO2R15 group, where R15 is selected from the group consisting of: (C1-C4) alkyl; -C(O)OR17 group, where R17 is selected from the group consisting of: (C1-C6) alkyl; or they form, together with the nitrogen atom to which they are attached, a saturated or partially saturated heterocyclic ring which is optionally substituted by one or more (C1-C6) alkyl; (C1-C2) alkylene-NR8R9, as mentioned above; COR10, where R10 is (C1-C6) alkyl; oxo; -SO2R11, where R11 is (C1-C4) alkyl or NR8R9, where R8 and R9 are as above; -COOR12, where R12 is H, (C1-C4) alkyl or (C1-C4) alkylene-NR8R9, where R8 and R9 are as above; and -CONR8R9, where R8 and R9 are as above; where R6, R8, R9, R10, R11, R12, R13, R14, R15, R17 and R19 groups in each case may have the same or different value if more than one group is present; and their N-oxide derivatives on the pyridine ring or their pharmaceutically acceptable salts. The compound is a phosphodiesterase 4 (PDE4) enzyme inhibitors.EFFECT: improved properties.19 cl, 26 tbl, 36 ex

Hypoallergenic variants of mal d 1, main malus domectica allergen // 2624030
FIELD: biotechnology.SUBSTANCE: aprotein is produced. It is a hypoallergenic mutant of the main Malus domectica Mal d 1 allergen TCD having SEQ ID NO: 1 for the use in immune therapy of patients allergic to Malus domectica and/or Betula verrucosa pollen. The resulting protein has an amino acid sequence. When the SEQ ID NO: 1 is aligned in it, there are either two substitutions, including the Asp residue substitution at position 25 and the Asn residue substitution at position 78, or one Asn residue substitution at position 78 of the sequence SEQ ID NO: 1, where these residues of Asp at position 25 and/or of Asn at position 78 are substituted by Ala residue. The invention allows producing a hypoallergenic mutant of the main Malus domectica Mal d 1 allergen which shows a reduced IgE reactivity compared to the specified Mal d 1 allergen with SEQ ID NO: 1.EFFECT: possibility of using in medicine for the treatment of allergic diseases.14 cl, 15 dwg, 3 tbl, 13 ex
ethods of obtaining molecular structures containing antigenic epitopes of topical allergens and signal peptides with immunoregulatory properties // 2622004
FIELD: biotechnology.SUBSTANCE: method for obtaining molecular structures with immunoregulatory properties containing antigenic epitopes of topical allergens and an ornithine decarboxylase signal peptide (ODCsig) is proposed. The gene encoding the protein-allergen by cloning is obtained, the ODCsig sequences are selected, the DNA sequences encoding the ODCsig signal peptides are cloned, the chimeric gene and the DNA constructs are developed to express the chimeric protein-allergens in bacterial cells.EFFECT: invention provides specific immunotherapy for patients with allergies.10 dwg, 2 tbl, 15 ex
ethod of treating and preventing chronic inflammatory diseases of nasopharynx associated with inhalation exposure to benzene and formaldehyde in children // 2618469
FIELD: medicine.SUBSTANCE: invention can be used to treat and prevent chronic inflammatory diseases of nasopharynx (CIDN) in children aged 4 through 10 years old, living in area of industrial enterprises impact in conditions of atmospheric air pollution with benzene and formaldehyde. Treatment is carried out by combined administration of the following medicinal products to children: "Tonsilgon N" preparation orally in a dose for children aged 4 through 6 years old - 10 drops 3-4 times a day; for children over 6 years - 1 pill 3-4 times a day, for 21 days course; "Multi-Tabs Junior" 1 tablet once a day for 21 days; "Eslidine" 1 capsule twice a day before meals in the morning and evening for 21 days; "Zodac" preparation 5 mg once a day in a dose for children aged 4 through 6 years old; 10 mg once a day for children over 6 years old, for 21 days course, and simultaneously with children medical treatment, starting from the third day of drug administration, pulsed low-frequency magnetotherapy is employed for 10 minutes daily or every other day for 10 days course on nose sinuses or submandibular regions in the form of two-inductor technique with transverse arrangement of inductors and feedback sensor position at right supraclavicular region.EFFECT: invention provides treatment and prevention of chronic inflammatory disease of nasopharynx associated with exposure to benzene and formaldehyde in children.5 cl, 5 tbl
Phenylpyrrole derivative // 2618228
FIELD: pharmacy.SUBSTANCE: invention relates to new derivatives of formula (I) Q: (A) or (B) phenylpyrrole, or pharmaceutically acceptable salts thereof, which are useful for prevention or treatment of diseases such as dementia, Alzheimer's disease, attention deficit, hyperactivity disorder, schizophrenia, epilepsy, "central" cramp, obesity, diabetes, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behavior-induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm, parasomnia, sleep-related traffic violation, insomnia and depression, or allergic rhinitis.EFFECT: increased compound application effeciency.13 cl, 3 tbl, 10 ex
Compositions for local use containing diamineoxydase, for treatment or prevention of diseases associated with high levels of histamine, accompanied by increased pain // 2616248
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to pharmaceutical industry and represents application of diamineoxydase to produce a pharmaceutical composition for treatment of diseases or pathologic conditions selected from the group consisting of migraine, fibromyalgia, spondylitis, and muscle contractures, characterized by local application of the composition.EFFECT: invention provides expansion of the arsenal for migraine, fibromyalgia, spondylitis and muscular contractures treatment.12 cl, 6 tbl, 7 ex

Hydrochloride of derivative purinona // 2615999
FIELD: chemistry.SUBSTANCE: invention relates to the unknown hydrochloride of 6-amino-9-[(3R)-1-(2-butinoil)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8 and its crystalline form. The compound has the properties of a selective inhibitor of Bruton's tyrosine kinase (Btk) and can be used as an agent for the prophylaxis and / or treatment of diseases associated with Btk involving B-cells and mast cells. Such diseases are allergic, autoimmune, inflammatory, embolic, bone disease or malignancy. The latter may be a non-Hodgkin's lymphoma. Crystals of hydrochloride of 6-amino-9-[(3R)-1-(2-butinoil)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8 have in the powder X-ray diffraction, at least, 2 or more peaks at angles 2θ selected from about 8.11, 8.43, 11.57, 12.73, 13.85, 14.20, 14.67, 14.91, 15.94, 16.64, 18.06, 19.74, 20.42, 21.05, 22.57, 23.21, 23.85 and 24.70 degrees. The hydrochloride crystalline form has an endothermic peak at the temperature of 216°C.EFFECT: said compound has a higher solubility and activity.10 cl, 4 dwg, 6 tbl, 13 ex
Cycloalkanecarboxylic acid derivatives as cxcr3 receptor antagonists // 2615993
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula 1 where R is hydrogen or a C1-4-alkyl group; R1 means a group selected from the group consisting of structures represented by formulas (Ia), where R2 means hydrogen or a C1-4-alkyl group; R3 means hydrogen, a halogen, CF3, CN or C1-4-alkyl and R4 means hydrogen, a halogen or a C1-4-alkyl; a=0, 1, or 2; b=0, 1, 2 or 3; C=1, 2 or 3, and Ra, Rb, Rc and Rd represent, independently of one another, H or a C1-4-alkyl; X means a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a hetero-atom selected from O and S, or CH(CH2)CH-; Y means hydrogen, a halogen, a C1-4-alkyl, C1-4-alcoxy or C1-4-hydroxyalkyl; Z means a C1-4-aliphatic hydrocarbon bridge optionally containing one double bond and/or one hetero-atom selected from O, S, N and N(CH3), or means a C2-4-aliphatic hydrocarbon bridge fused with a C3-6-cycloalkyl, optionally containing one or more double bonds or with a phenyl ring, or means a C1-4-aliphatic hydrocarbon bridge substituted with a spiro-C3-6-cycloalkyl, optionally containing one or more double bonds; or its pharmaceutically acceptable salt, or a stereoisomer, or a pharmaceutically acceptable salt of the stereoisomer. The compounds according to the invention are obtained due to reductive amination of the benzaldehyde of formula 4 by means of a primary amine R1-NH2, the introduction in the interaction of the obtained secondary amine of formula 2 with ether formyl - or oxocyclohexanecarboxylic acid of formula 3, where X, Y, Z, R1, R, Ra, Rb, Rc, Rd, b and c have the meanings as specified for formula 1, and R' means -CHO or =O, and, optionally, the hydrolysis of the obtained ester of formula 1. The invention also relates to an intermediate compound of formula 2 or a salt thereof. The compound of formula 1 according to the invention is intended for use in the preventive and / or therapeutic treatment of a disease or disorder mediated by CXCR3 receptor as a medicament or as part of a pharmaceutical composition.EFFECT: cycloalkanecarboxylic acid derivatives as CXCR3 receptor antagonists.20 cl, 6 tbl, 160 ex
ethod for production of pharmaceutical composition with fexofenadine, providing anti-allergic and anti-inflammatory effect // 2614961
FIELD: pharmacy.SUBSTANCE: pharmaceutical composition for fexofenadine gel preparation contains the following auxiliary components: thickener - Carbopol, neutralizing agent - sodium hydroxide 5% solution, glycerin and purified water. First, a hydrophilic base is prepared - carbopol is mixed with glycerol at a ratio of 1:20, with vigorous stirring, purified water is added, and the resulting system is stirred until complete homogenization, fexofenadine is then dissolved in 5% sodium hydroxide solution, the resulting fexofenadine alkaline solution is gradually added to the hydrophilic base with vigorous stirring to obtain a gel composition with a pH of 6.5. The gel is stored at a temperature of 15÷25°C for 2 years, if an increased storage life of the gel composition is required, nipagin or benzalkonium chloride is introduced.EFFECT: fexofenadine gel has a high therapeutic efficacy with minimal side effects, and low cost.1 tbl, 4 ex

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex

ilk-based protein hydrolysates and infant nutritional compositions prepared from them // 2612008
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns composition for oral tolerance stimulation in babies or subjects requiring it, containing milk-based protein hydrolysate, obtained by processing solution of milk-based protein material with at least one trypsin-like endopeptidase, obtained from microorganism Kutzneria albida, and at least one chymotrypsin-like endopeptidase, obtained from microorganism Nocardiopsis SP. or Metarhizium anisopliae. Group of inventions also concerns composition for reducing risk of allergy in babies or subjects requiring it, containing milk-based protein hydrolysate; composition for reducing severity or frequency of allergy in infants or in next period of life in babies or subjects requiring it, containing milk-based protein hydrolysate.EFFECT: group of inventions provides production of hydrolysates, which have low residual antigenicity and low allergenicity.9 cl, 1 ex, 3 dwg, 1 tbl
ethod of increasing efficiency of therapy of autoimmune diseases, such as rheumatoid arthritis // 2611341
FIELD: pharmaceutics.SUBSTANCE: group of inventions is disclosed to reduce undesirable reaction of immunosuppressive drugs for treating autoimmune diseases. There are presented: pharmaceutical composition containing iguratimod or its salt and one or more immunosuppressive agents selected from nucleic acid synthesis inhibitors (e.g., methotrexate) or steroid anti-inflammatory drugs (e.g., prednisolone), device and kit of above purpose.EFFECT: technical result consists in reduction of hepatocellular damage and elimination of reticulocytopenia caused by said immunosuppressants.12 cl, 5 tbl, 9 ex

New allergen // 2608494
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to novel horse allergens, and can be used in medicine for prophylactic or therapeutic treatment or diagnostics of type I allergy in horses. Horse allergen is obtained, which represents secretoglobin with molecular weight of 15 kDa in non-reducing conditions and contains first peptide chain with molecular weight of approximately 5 kDa and second peptide chain with molecular weight of approximately 10 kDa, linked to each other. Recombinant form of said allergen is also obtained.EFFECT: invention enables to obtain recombinant horse allergen with completely determined amino acid sequence.13 cl, 10 dwg, 3 tbl, 8 ex

odification of group 6 poaceae (bluegrass) allergens with low allergenic capacity due to mutagenesis of proline residues // 2607373
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology, namely to recombinant modifications of group 6 Poaceae (bluegrass) allergens, and can be used in medicine for preventing or treating type 1 allergies, in initiation of which group 6 bluegrass allergens are involved. Recombinant allergen Phl p 6 is obtained, in which prolines, corresponding in linearized form to prolines in positions 29, 30, 57 and 79 of amino acid sequence of wild type protein Phl p 6 in compliance with SEQ ID NO: 2, are mutated separately or in combination by point mutations, selected from deletions and substitutions of amino acids.EFFECT: present invention enables to obtain recombinant allergen Phl p 6 with low IgE reactivity, compared to existing non-mutated allergens, and with substantially preserved T-lymphocytes reactivity at the same time.12 cl, 20 dwg, 2 tbl, 3 ex

Purified extract separated from pseudolysimachion rotundum var subintegrum with high content of active ingredient, its production and composition containing the above extract as an active ingredient to prevent or treat inflammation, allergies and asthma // 2606768
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to the purified extract, broken up using butanol (ATS1) from the Pseudolysimachion rotundum var subintegrum extract. Purified extract broken up using butanol (ATS1) from the Pseudolysimachion rotundum var subintegrum extract, for the prevention and treatment of inflammatory diseases, received in accordance with the method comprising: addition of ethanol to the dried Pseudolysimachion rotundum var subintegrum and carrying out the extraction with cold water; further carrying out the extraction with hot water under reflux with the receipt of the 1st extract at the 1st stage; suspending of said 1st extract in water, adding butanol to said extract, fractionation with obtaining a water layer and butanol layer and the collection of butanol layer with the receipt of purified extract, broken up using butanol (ATS1), under certain conditions, wherein obtain a extract containing verprozid, veratric acid, katalpozid, pikrozid II, izovanilloilkatalpol and 6-O-veratroilkatalpol in certain proportions (versions). A pharmaceutical composition. Functional food product.EFFECT: above described extract Pseudolysimachion rotundum var subintegrum has increased anti-inflammatory effect.4 cl, 15 dwg, 10 tbl, 8 ex

Derivatives of 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indole-acetic acid and use thereof as prostaglandin d2 receptor modulators // 2596823
FIELD: chemistry.SUBSTANCE: invention relates to derivatives of 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indole-acetic acid with formula (I) or pharmaceutically acceptable salt of such compound, where R1 and R2 represent independently of each other hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy group, halogen, trifluoromethoxy group or trifluoromethyl; R3 represents hydrogen, (C1-C4)alkyl, (C1-C2)alkoxy-(C2-C3)alkyl, (C1-C4)fluoroalkyl or (C3-C6)cycloalkyl-(C1-C2)alkyl; and R4 represents heteroaryl group, which is unsubstituted or mono-substituted, where substitutes are independently selected from group comprising halogen, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy group, (C1-C4)fluoroalkyl and phenyl; where term "heteroaryl" denotes 5-10-member monocyclic or bicyclic aromatic ring containing one nitrogen atom and optionally one additional heteroatom selected from oxygen, nitrogen and sulphur. Invention also relates to the pharmaceutical composition based on compound with formula (I) and application of compound with formula (I).EFFECT: obtaining new heterocyclic compounds having antagonistic activity in relation to CRTH2 receptor.17 cl, 19 dwg, 51 ex

Food composition with probiotics // 2595396
FIELD: food industry.SUBSTANCE: disclosed is use of baby food for production of a nutritional composition for baby feeding. Baby food contains from 5 to 16 en% protein, from 30 to 60 en% fat, from 25 to 75 en% carbohydrates, as well as Bifidobacterium breve and Lactobacillus paracasei.EFFECT: invention provides higher level of Bifidobacteria and Lactobacilli in feces in infants and control of their population in intestine at level of types to values close to values observed in breastfed children.13 cl, 1 dwg, 4 tbl, 10 ex

Pharmaceutical product containing extract(s) of allergen tongs and method for production thereof // 2593778
FIELD: medicine. SUBSTANCE: invention refers to medicine, particularly to pharmaceutical product containing extract of allergen, which contains at least one extract bodies mites and extract faecal particles tongs, where pharmaceutical product is quickly decomposing sublingual tablet for treating and/or preventing allergies or allergic asthma. Method of producing allergen mites involves the following steps: selecting fractions bodies mites and/or fractions faecal particles mites; optional combination of several fractions; extraction of allergens fraction bodies mites and/or fractions faecal particles mites; determination of concentration of allergen group 1 and 2; mixing one or more extracts bodies tongs with one or more extracts faecal particles mites. EFFECT: invention implementation allows to produce pharmaceutical product containing extract of allergen tongs with controlled ratio of allergen group 1 to allergen Group 2. 17 cl, 4 tbl, 1 dwg, 7 ex

Allergens produced by recombinant methods // 2592674
FIELD: biotechnology. SUBSTANCE: present invention relates to biotechnology, specifically to novel dog allergens, and can be used in medicine. Allergen Can f 4 is produced by recombinant method. Obtained allergen can be used during in vitro diagnosing or treating allergy, caused by dandruff or dogs wool. EFFECT: present invention enables to obtain allergen Can f 4 by recombinant method with completely determined amino acid sequence. 11 cl, 10 dwg, 5 tbl, 1 ex

Selective glycosidase inhibitors and use thereof // 2592285
FIELD: chemistry. SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, where each R represents H; R1 and R2 are independently selected from a group consisting of H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy and -(CH2)n-cyclopropyl, where n equals 1 or 2; or R1 and R2 can be bonded together with a nitrogen atom to which they are bonded to form azetidine, pyrrolidine or isoxazolidine, where said C1-6alkyl is optionally substituted by fluorine or hydroxy; R3 is selected from a group consisting of C1-8alkyl, C2-8alkenyl, C3-6cycloalkyl, phenyl and pyridine, each optionally substituted with 1-3 substitutes selected from fluorine and OH; R4 is selected from a group consisting of H, F or C1-8alkyl; or R3 and R4 and a carbon atom to which they are bonded, can be combined together to form vinyl or 3-7-membered carbocyclic ring, wherein said 3-7-member carbocyclic ring optionally contains a double bond; and R5 is selected from H, F and OH; provided that when R4 represents F while R5 is other than OH. Invention also relates to specific derivatives of pirano[3,2d]thiazole. Disclosed compounds are intended for producing a pharmaceutical composition possessing inhibitory activity on O-GlcNAcase, containing an active ingredient in an effective amount of compound or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable carrier. EFFECT: technical result is a compound for selective inhibition of glycosidase. 15 cl, 1 tbl, 218 ex
ixture of indigestible oligosaccharides to stimulate immune system // 2591831
FIELD: food industry.SUBSTANCE: group of inventions relates to food industry, specifically to a nutritional composition, which is not human milk and contains fucosyllactose and betagalactooligosaccharide having structure [galactose]n-glucose, where n equals a whole number from 2 to 60, and have more than 80 % of beta-1,4 and beta-1,6 links; and to use of said composition to provide nourishment children, elderly and patients with cancer and/or patients infected by HIV, as well as for treating and/or preventing development of viral infections, immune diseases and/or disease which can be prevented and/or cured by amplification of Th1 response and/or Th1/Th2 balance, and for enhancing response to vaccination.EFFECT: group of inventions provides a synergetic effect on boosting Th1 response.14 cl, 3 ex, 1 tbl

Pharmaceutical composition for oral administration with improved solubility and/or absorbability // 2589701
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition for oral administration containing 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide, its salt or solvate as active pharmaceutical ingredient and fumaric acid as acid additive. Fumaric acid is contained in an amount of 0.25 to 5 weight fractions on the weight ratio of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamid.EFFECT: also described is method of stabilization, improve solubility and improved intestinal absorption of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide by adding of fumaric acid to pharmaceutical composition.12 cl, 5 dwg, 8 tbl, 9 ex

ethods of treating allergic diseases // 2587061
FIELD: medicine.SUBSTANCE: present invention relates to a method of treating allergic diseases by administering a therapeutically effective amount of a benzo[b]azepine TLR8 receptor agonist VTX-378 - (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide or a pharmaceutically acceptable salt thereof. Said benzo[b]azepine VTX-378 is administered intranasally in a dosage form containing a single dose of 25 mcg to 1,000 mcg. Administration is daily, three times a week (intermittently), twice a week, once a week, every 14 days, once a month or once every 6-8 weeks.EFFECT: treatment with benzo[b]azepine VTX-378 significantly reduced allergic reaction in an experimental model of allergic rhinitis, sensitised with ragweed pollen allergen, and showed an increase in volume of nasal cavity.19 cl, 14 dwg, 2 tbl, 3 ex

Pyruvamide compounds as inhibitors of allergen dust mites 1 group, which is peptidase, and use thereof // 2586215
FIELD: pharmaceuticals.SUBSTANCE: invention relates to the field of medicinal compounds. Proposed is pyruvate-amide compounds of formula (X), which inhibit the allergen is dust mite group 1, which is a peptidase, e.g., Der p 1, Der f 1, Eur m 1.EFFECT: also provided are pharmaceutical compositions comprising said compounds and use of said compounds and compositions for inhibiting allergen 1 group is a peptidase dust mites, and for the treatment of diseases and disorders mediated by allergen dust mite group 1, in particular asthma, rhinitis, allergic conjunctivitis, atopic dermatitis, allergic condition caused by dust mite allergic condition caused by dust mite allergen group 1 and atopy in dogs.51 cl, 3 dwg, 1 tbl, 1 ex

Versions of group of 5 allergens of true grasses with reduced allergenicity resulting from mutagenesis of proline residues // 2575606
FIELD: chemistry.SUBSTANCE: invention relates to field of biochemistry, in particular to hypoallergenic polypeptide of Grass family. Also disclosed are DNA molecule, which codes said hypoallergenic polypeptide, recombinant expression vector, containing said DNA molecule, and host cell, transformed by means of said DNA molecule or said vector, for obtaining said hypoallergenic polypeptide. Disclosed are method for obtaining said hypoallergenic polypeptide, application of said hypoallergenic polypeptide or said DNA molecule for obtaining medication and pharmaceutical preparation for prevention or treatment of type 1 allergies, which contains efficient quantity of hypoallergenic polypeptide.EFFECT: invention makes it possible to efficiently treat type 1 allergies.14 cl, 8 tbl, 9 ex, 24 dwg

Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists // 2573828
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new aminoalkylpyrimidine derivatives of formula (I) or their pharmaceutically acceptable salts exhibiting the properties of histamine H4 receptor antagonists. The compounds are applicable in respiratory diseases, including asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD); ophthalmic diseases, including conjunctivitis, dry eye syndrome, cataract; dermatological diseases, including eczema, dermatitis (e.g., atopic dermatitis), psoriasis, urticaria, pemphigus, dermatitis herpetiformis, cutaneous vasculitis, itch; inflammatory intestinal diseases, including nonspecific ulcerative colitis, Crohn's disease; and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, cutaneous lupus, systemic lupus erythematosus, widespread vasculitis and graft rejection. In formula IR1 and R2 form together with N atom to which they are bound, a saturated heterocyclic group containing one nitrogen atom and free frpm any other heteroatoms; the above heterocyclic group is substituted by one -NRaRb group and optionally substituted by one or more C1-4alkyl groups; wherein the heterocyclic group represents a 4-7-merous monocyclic group; Ra represents H or C1-4alkyl; Rb represents H or C1-4alkyl; R3 represents H or C1-8alkyl; R4 represents a) C1-8alkyl optionally substituted by one or more halogens; b) C3-10cycloalkyl-C0-4alkyl; c) aryl-C0-4alkyl or d) 5-6-merous heteroaryl-C0-4alkyl, wherein the radicals b), c) or d) may be substituted as specified in the patent claim; n equals to 1 or 2; each R5 independently represents H or C1-8alkyl.EFFECT: compounds can find application in treating or preventing an allergic, immune system or inflammatory disease, pain or cancer.22 cl, 18 ex

Phenyloxadiazole derivatives as pgds inhibitors // 2572608
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I), where R1 is hydrogen or C1-C6alkyl; R2 is hydrogen and R3 is hydroxy(C1-C6)alkyl; or pharmaceutically acceptable salts thereof. The invention also relates to methods of producing compounds of formula (I), intermediate compounds given in paragraphs 14-19 of the claim, and a method of producing an intermediate compound according to paragraph 17 of the claim.EFFECT: obtaining compounds of formula as PGD2 synthase inhibitors and intermediate compounds for production thereof.20 cl, 3 ex

ethod of obtaining allergen extract // 2572230
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and are intended for treatment of allergy. To obtain allergen extract contact of initial material with liquid extraction means with obtaining mixture is realised. Mixture is subjected to first degree of separation. Contact of residue of initial material with means for extraction of allergens is performed. Mixture is subjected to second stage of separation with obtaining raw extract of allergen, from which low-molecular fraction is removed. The procedure is repeated until allergen extract has conductivity lower than 1000 mcSm/cm at 3-5°C with obtaining purified native allergen extract. Acidification to pH 2-4 is carried out. Then, low-molecular fraction is removed and pH is brought to 7-8 with obtaining depigmented allergen extract. Contact with glutaraldehyde is realised. Molecules with molecular size smaller than 100 kDa are removed. The procedure is repeated until allergen extract has conductivity lower than 210 mcSm/cm at 3-5°C and/or glutaraldehyde is absent. Allergen extract is a component of composition and vaccine for allergy treatment.EFFECT: application of group of inventions makes it possible to obtain allergen, possessing reduced ability to bind IgE and suitable for immunotherapy.26 cl, 10 dwg, 11 tbl, 8 ex

Composition for interleukine-4 cytokine gene silencing // 2563989
FIELD: medicine.SUBSTANCE: invention concerns a composition for the interleukin-4 cytokine gene silencing by means of an RNA interference mechanism, consisting of a cationic LTP peptide dendrimer described by formula (Arg)8(Lys)4(Lys)2Lys-Ala-Cys-NH2 used as a carrier, and two siRNA molecules described by formulas 5-UUGAUGAUCUCCUGUAAGGtt-3 and 5-AAAGAUGUCUGUUACGGUCtt-3.EFFECT: creating the low-toxic composition used for interleukin-4 gene silencing.3 cl, 18 dwg, 14 tbl, 4 ex

Fexofenadine microcapsules and compositions containing thereof // 2563623
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to field of pharmaceutics and represents pharmaceutical composition, containing water-suspendable combined granulate of microcapsules with immediate release and inactive ingredients, where said microcapsules are microcapsules with disguised taste and represent fexofenadine, covered with water-insoluble polymer coating; as well as method for obtaining said composition and method for treating inflammation-associated condition, including introduction of said composition to patient.EFFECT: realisation of invention provides improved disguise of fexofenadine taste along with immediate release of active ingredient.22 cl, 65 tbl, 28 dwg

Novel crystalline forms of 4,4'-[4-fluoro-7({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl} ethynyl)-2-methyl-1h-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid // 2560147
FIELD: chemistry.SUBSTANCE: invention relates to novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid.EFFECT: obtaining novel compounds.18 cl, 16 dwg, 7 tbl, 24 ex

Indole derivative and its pharmaceutical application // 2556216
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to compound, represented by the following formula , or its pharmaceutically acceptable salt. In claimed formula each symbol has values, determined in formula of invention. Versions of formula [I] compound and particular compounds are also objects of invention. In addition, invention relates to pharmaceutical composition, ITK inhibitor and means for treatment or prevention of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection and other diseases and methods of treating said diseases.EFFECT: claimed compounds inhibit induced T-cellular kinase (ITK).32 cl, 86 tbl, 387 ex

Antiallergic agent // 2553354
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents an anti-allergic agent containing polysaccharide containing galactose, glucose and rhamnose as ingredients, wherein polysaccharide contains galactose, glucose and rhamnose in molar ratio 3-5:1-3:1, and polysaccharide has certain structure.EFFECT: invention provides extending the range of antiallergic agents.12 cl, 6 ex, 6 dwg, 1 tbl

Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases // 2552929
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. A medication represents derivatives of glutarimides of the general formula (I) or their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions and a method of treatment.EFFECT: ensured by the application of non-toxic derivatives of the said glutarimides for the treatment of eosinophilic diseases, mainly of an allergic origin.16 cl, 12 tbl, 7 ex

Dosage form containing desloratadine and method for producing it // 2550958
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a tabletted oral dosage form containing desloratadine in an amount of 3 to 15%, processing additives and a pharmaceutically acceptable excipient. The processing additives consist of sodium croscarmellose, magnesium stearate and povidone. The excipient represents a mixture of lactose disaccharide and microcrystalline cellulose polysaccharide in ratio from 2:1 to 8:1. Lactose and microcrystalline cellulose have an average particle size from 30 to 200 mcm. Producing the table involves granulating desloratadine, lactose and microcrystalline cellulose.EFFECT: invention provides reducing granulate compression force, increasing process capability and maintaining the high quality of the tablets.9 cl, 4 tbl, 4 ex

Allergotropines for treatment of allergy caused by house dust mites // 2548727
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of medicine, namely to immunology and allergology, and can be used for the treatment of allergy to house dust mites. For this purpose an allergotropine is obtained by a method of chemical conjugation of an allergoid and synthetic highly molecular immunomodulator Polyoxidonium. The allergotropine contains 1000±200 PNU of the allergoid of house dust mites Dermatophagoides pteronyssinus or Dermatophagoides farinae and 6.25±1.25 mg of Polyoxidonium.EFFECT: obtaining the allergotropines, based on the allergoid forms of allergens of house dust mites Dermatophagoides pteronyssinus or Dermatophagoides farinae, possessing more expressed immunogenic and hyposensitising properties in comparison with the native allergen, makes it possible to carry out the effective treatment of allergy by ASIT method.2 ex, 2 tbl, 2 dwg
Food compositions containing punicalagins // 2542497
FIELD: pharmacology.SUBSTANCE: invention mainly relates to a food composition, including punicalagins.EFFECT: improved action in respect to health improvement.8 cl, 1 tbl, 1 ex

Nutritional composition containing strains bifidobacterium longum and relieving symptoms of food allergy, especially in infants and children // 2539514
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to microbiology. What is presented is using the strain Bifidobacterium longum NCC 2705 (CNCM-I2618) for preparing a complete nutrient composition used for relieving symptoms of allergy to food in the patients suffering allergies caused by ingestant allergens.EFFECT: composition provides the secondary prevention of allergic reactions caused by the above ingestant allergens.16 cl, 7 dwg, 1 ex

Complex preparation based on allergens of birch pollen and muramylpeptides // 2537225
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to complex injection preparation for treating polynoses by ASIT method. Said preparation is obtained by simple mixing birch pollen allergoid and muramylpeptide without carrying out chemical conjugation of components, with 2 mg of muramylpeptide being added per 1000 PNU dose.EFFECT: invention provides considerable enhancement of immune response and stimulates high level of production of specific IgG-antibodies, as well as makes it possible to reduce course of treatment of polynoses, which reduces possibility of complications.1 dwg, 2 tbl

Composition for reducing injury caused by uv radiation // 2537187
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.EFFECT: invention provides creation of stable and safe composition, which can be applied daily.10 cl, 37 ex, 7 dwg

Pharmaceutical composition containing desloratadine (versions) // 2537169
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and medicine, namely to manufacturing drug preparations for treating allergic diseases, such as allergic rhinitis and urticaria. According to the first version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including citric acid, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, lactose, magnesium stearate, and talc. According to the second version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including Pearlitol 100SD-Mannitol, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, magnesium stearate, and talc. According to the third version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, colloidal silicone dioxide, and sodium sodium stearyl fumarate. According to the fourth version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, Pearlitol 100SD-Mannitol, magnesium stearate, and talc. The pharmaceutical composition is presented in the form of a film-coated tablet.EFFECT: pharmaceutical composition according to the invention is storage-stable and releases the active substance quickly in the gastrointestinal tract.10 cl, 9 tbl, 20 ex

Nutritional composition containing apple extract and reducing food allergy symptoms, especially in children // 2536916
FIELD: food industry.SUBSTANCE: invention relates to nutritional compositions based on a natural extract. One proposes the application of an apple extract containing polyphenols for the manufacture of a complete nutritional composition for the reduction of symptoms of allergy caused by food in patients suffering from allergy caused by food allergens. The apple extract is enriched with polyphenols by at least 1.5 times relative to the unpurified apple extract. The composition contains 0.1% - 1 wt % of the apple extract.EFFECT: proposed composition has no effect on the patients` sensitisation to the said allergens.13 cl, 6 dwg
Composition containing bacterial waste products useful for human body // 2535152
FIELD: biotechnology.SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.4 cl, 5 ex

Antioxidant composition // 2535099
FIELD: chemistry.SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.EFFECT: invention ensures an increase of the antioxidant effect of the composition.4 cl, 5 dwg, 31 ex
ethod of treating allergic diseases // 2531100
FIELD: medicine.SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.1 ex

Hypoallergenic dermatological composition // 2526833
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.8 cl, 2 ex, 2 tbl, 3 dwg

Prevention and treatment of allergic diarrhoea // 2522240
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.7 cl, 1 dwg

Treatment of dermatological allergic states // 2521357
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, particularly to method of treatment of dermatological allergic state. Proposed method comprises injection of efficient amount of [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-silt][7-fluorine-1-(2-metoxyethyl)-4-trifluorometoxy-1H-indol-3-il]methanon or its appropriate N-oxide, pharmaceutically acceptable salt or solvate.EFFECT: higher efficiency.5 cl, 1 ex, 1 tbl
 
2550941.
Up!